Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Cash from Investing Activities (2023 - 2025)

Historic Cash from Investing Activities for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $2.5 million.

  • NewAmsterdam Pharma's Cash from Investing Activities rose 344133.33% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$216.0 million, marking a year-over-year decrease of 3203601.19%. This contributed to the annual value of -$62.8 million for FY2024, which is 26176666.67% down from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Cash from Investing Activities stood at $2.5 million, which was up 344133.33% from -$159.1 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Cash from Investing Activities' 5-year high stood at $2.9 million during Q1 2025, with a 5-year trough of -$159.1 million in Q2 2025.
  • Its 3-year average for Cash from Investing Activities is -$19.7 million, with a median of -$9000.0 in 2023.
  • Per our database at Business Quant, NewAmsterdam Pharma's Cash from Investing Activities plummeted by 207253333.33% in 2024 and then surged by 344133.33% in 2025.
  • Over the past 3 years, NewAmsterdam Pharma's Cash from Investing Activities (Quarter) stood at -$3000.0 in 2023, then tumbled by 2072533.33% to -$62.2 million in 2024, then skyrocketed by 104.03% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, -$159.1 million for Q2 2025, and $2.9 million during Q1 2025.